07.01.2019 • NewsClariantElaine Burridge

Clariant Studies Saudi Alkoxylates JV

Clariant Studies Saudi Alkoxylates JV (c) Clariant
Clariant Studies Saudi Alkoxylates JV (c) Clariant

Clariant and SABIC affiliate Saudi Kayan have signed a Memorandum of Understanding (MoU) to study the formation of an alkoxylates manufacturing joint venture.

The companies will evaluate establishing a plant to produce alkoxylates, a derivative of ethylene oxide, at Saudi Kayan’s complex in Jubail Industrial City, Saudi Arabia.

Clariant, which uses alkoxylates in various applications in the home care, personal care and industrial sectors, will provide its production technology, while Saudi Kayan will supply the raw materials.

The MoU is another cooperation resulting from SABIC’s purchase of a 24.99% stake in the Swiss specialty chemicals company last September. 

In separate news, Clariant has reduced its stake in the Stahl group to 14.8% from 19.7%, although said it will remain a financial investor in the company.

Netherlands-based Stahl is a producer of chemicals, dyes and coatings for leather and other applications. Clariant sold its leather services business to Stahl in 2014 for around 85 million Swiss francs and a 24% stake in the Dutch group.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.